Divi's Laboratories reported a 10% increase in revenue from operations for Q4FY26, reaching Rs 2,831 crore compared to Rs 2,585 crore in the same quarter last year. The pharmaceutical company also announced a final dividend of Rs 30 per equity share for FY26, pending approval at the upcoming 36th Annual General Meeting.
The company's Profit After Tax (PAT) surged 29% sequentially in Q4FY26, amounting to Rs 751 crore, compared to Rs 583 crore in the previous quarter. The topline grew by 8% quarter-on-quarter, reflecting robust operational performance.
Expenses for the quarter under review increased to Rs 2,023 crore, up from Rs 1,838 crore in Q3FY26 and Rs 1,807 crore in Q4FY25. These expenses were primarily attributed to materials consumed, stock-in-trade purchases, employee benefits, and finance costs.
Divi's Laboratories reported a significant forex gain of Rs 90 crore for the current quarter, a substantial increase from the Rs 10 crore gain in the corresponding quarter of the previous year.
For the full financial year 2025-26, the company achieved a consolidated total income of Rs 11,067 crore, up from Rs 9,712 crore in the previous year. Profit Before Tax (PBT) for the year stood at Rs 3,388 crore, factoring in a Rs 74 crore impact from labor codes.
Background
Divi's Laboratories has consistently shown strong financial performance, with significant growth in both revenue and profit margins over the past few years. The company's strategic investments in research and development, coupled with efficient cost management, have positioned it well in the competitive pharmaceutical industry.
Looking ahead, Divi's Laboratories' financial performance indicates strong growth potential, with investors closely watching the approval of the proposed dividend and future market developments.
